HHS Invests $100 Million for Great American Recovery
The U.S. Health and Human Services (HHS) has developed a comprehensive plan to strengthen prevention, expand treatment and carry out the the Great American Recovery.
$1.6 Million Grant Awarded for Hepatitis B Vaccine Research
The Centers for Disease Control and Prevention (CDC) has awarded an unsolicited $1.6 million grant for vaccine research to Danish researchers whose studies have been challenged by mainstream scientists but championed by anti-vaccine activists
$2.7 Million Grant Awarded for NSCLC Research
Trethera Corp. has been awarded a new $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
Study Shows Nasal Spray Protects Against Any Flu Strain
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
FDA Approves Merck’s KEYTRUDA QLEX for Solid Tumor Indications
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
New Assay to Accurately Measure FXI Levels During IVIG Therapy
GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.
Novel Flu Vaccine Offers Broad Protection Against Multiple Flu Viruses
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.
Flu Vaccine Even with Infection Reduces Risk of Heart and Stroke
A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.
High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
FDA Approves Gene Therapy for Rare Immune Disorder
FDA has approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe leukocyte adhesion deficiency type I.